041910 — Polaris AI Pharma Balance Sheet
0.000.00%
Last trade - 00:00
- KR₩94bn
- KR₩66bn
- KR₩64bn
- 82
- 34
- 29
- 45
2019 December 31st | R2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | ARS | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Cash | |||||
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 40,324 | 52,123 | 50,991 | 30,590 | 27,454 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 11,637 | 12,650 | 15,444 | 14,837 | 16,273 |
Total Inventory | |||||
Prepaid Expenses | |||||
Total Current Assets | 66,071 | 81,175 | 84,164 | 67,731 | 64,342 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 32,564 | 31,952 | 31,306 | 31,138 | 30,592 |
Net Intangible Assets | |||||
Long Term Investments | |||||
Other Long Term Assets | |||||
Total Assets | 116,426 | 129,221 | 134,361 | 124,319 | 121,899 |
Accounts Payable | |||||
Payable / Accrued | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 11,559 | 10,166 | 9,037 | 7,036 | 4,871 |
Long Term Debt | |||||
Capital Lease Obligations | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Deferred Income Tax | |||||
Total Other Liabilities | |||||
Total Funded Status | |||||
Total Liabilities | 13,705 | 13,052 | 11,062 | 8,230 | 6,266 |
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Treasury Stock | |||||
Unrealized Gain / Loss | |||||
Other Equity | |||||
Total Equity | 102,720 | 116,169 | 123,299 | 116,089 | 115,633 |
Total Liabilities & Shareholders' Equity | 116,426 | 129,221 | 134,361 | 124,319 | 121,899 |
Total Common Shares Outstanding |